Kelun’s TROP2 ADC plus Keytruda improves outcomes in first-line lung cancernews2025-11-24T15:59:45+00:00November 24th, 2025|Endpoints News|
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis datanews2025-11-24T15:39:54+00:00November 24th, 2025|Endpoints News|
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeuticsnews2025-11-24T12:30:38+00:00November 24th, 2025|Endpoints News|
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 winnews2025-11-24T12:13:03+00:00November 24th, 2025|Endpoints News|
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trialsnews2025-11-24T12:10:32+00:00November 24th, 2025|Endpoints News|
Craig Crews, Mikael Dolsten raise $32M for Quarry Theranews2025-11-24T12:00:59+00:00November 24th, 2025|Endpoints News|
Nobel laureate Carolyn Bertozzi to rejoin Lilly boardnews2025-11-24T09:15:20+00:00November 24th, 2025|Endpoints News|
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and morenews2025-11-22T11:00:03+00:00November 22nd, 2025|Endpoints News|
Top Makary aide Jain-Nagpal remains at the FDA after White House pushbacknews2025-11-21T20:25:04+00:00November 21st, 2025|Endpoints News|
AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the USnews2025-11-21T19:33:41+00:00November 21st, 2025|Endpoints News|
